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ABSTRACT
Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease (IBD) characterized by inflammation of
the mucosal layer of the colon. Diagnosis of UC is based on clinical symptoms, and then confirmed based on endoscopic,
histologic and laboratory findings. Feature selection and machine learning have been previously used for creating models to
facilitate the diagnosis of certain diseases. In this work, we used a recently developed feature selection algorithm (DRPT)
combined with a support vector machine (SVM) classifier to generate a model to discriminate between healthy subjects and
subjects with UC based on the expression values of 32 genes in colon samples. We validated our model with an independent
gene expression dataset of colonic samples from subjects in active and inactive periods of UC. Our model perfectly detected all
active cases and had an average precision of 0.62 in the inactive cases. Compared with results reported in previous studies
and a model generated by a recently published software for biomarker discovery using machine learning (BioDiscML), our final
model for detecting UC shows better performance in terms of average precision.
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gut with an increasing health burden1. Ulcerative
colitis (UC) and Crohn’s disease are the two most common forms of chronic IBD with UC being more widespread than Crohn’s
disease2. There is no cure for UC3 and people with the disease alternate between periods of remission (inactive) and active
inflammation2. The underlying causes of UC are not completely understood yet, but it is thought to be a combination of
genetic, environmental and psychological factors that disrupt the microbial ecosystem of the colon3, 4. Genome-wide association
studies (GWAS) have identified 240 risk loci for IBD5 and 47 risk loci specifically associated with UC6. However, the lower
concordance rate in identical twins of 15% in UC compared with 30% in Crohn’s disease indicates that genetic contribution in
UC is weaker than in Crohn’s disease7. Thus, using gene expression data for disease diagnostic might be more appropriate for
UC than using GWAS data, as it has been done for Crohn’s disease8.
There are several features used for clinical diagnosis of UC including patient symptoms, and laboratory, endoscopic and
histological findings7. Boland et at9 carried out a proof-of-concept study for using gene expression measurements from colon
samples as a tool for clinical decision support in the treatment of UC. The purpose of Boland et al’s study was to discriminate
between active and inactive UC cases; even though, they only considered gene expression of eight inflammatory genes instead
of assessing the discriminatory power of many groups of genes, they concluded that mRNA analysis in UC is a feasible
approach to measure quantitative response to therapy.
Machine learning-based models have a lot of potential to be incorporated into clinical practice10; specially in the area of
medical image analysis11, 12. Supervised machine learning has already proved to be useful in disease diagnosis and prognosis
as well as personalized medicine13, 14. In IBD, machine learning has been used to classify IBD paediatric patients using
endoscopic and histological data15, to distinguish UC colonic samples from control and Crohn’s disease colonic samples16,
and to discriminate between healthy subjects, UC patients, and Crohn’s disease patients17. Here we apply a machine learning
classifier on gene expression data to generate a model to differentiate UC cases from controls. Unlike previous studies16, 17, we
combined a number of independent gene expression data sets instead of using a single data set to train our model, and, by using
feature selection, we were able to identify 32 genes out of thousands genes for which expression measurements were available.
The expression values of these 32 genes is sufficient to generate a SVM model to effectively discriminate between UC cases
and controls. Our proposed model perfectly detected all active cases and had an average precision of 0.62 in the inactive cases.
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Methods
Data gathering
We searched the NCBI Gene Expression Omnibus database (GEO) for expression profiling studies using colonic samples
from UC subjects (in active and inactive state) and controls (healthy donors). We identified five datasets (accession numbers
GSE115218, GSE1122319, GSE2261920, GSE7521421 and GSE945216). As healthy and Crohn’s disease subjects were used as
controls in GSE945216, this data set was excluded from our study. We used three of the datasets for model selection using
5-fold cross-validation, and left one dataset for independent validation (Table 1). We partitioned the validation dataset into two
datasets: Active UC vs controls, and inactive UC vs controls.
Accession # of # of Description of Platform # of genes Usage
number controls UC cases samples (features)
GSE115218 4 4 Mucosal biopsies from Affymetrix Human Genome 19,353 Model
uninflammed colonic tissues U133A Array and Affymetrix selection
Human Genome U133B Array
GSE1122319 24 25 Biopsies from Agilent-012391 Whole 18,626 Model
uninflammed sigmoid colon Human Genome Oligo selection
Microarray G4112A
GSE2261920,22 10 10 Mucosal colonic tissue Affymetrix Human Genome 22,189 Model
from discordant twins U133 Plus 2.0 Array selection
GSE75214-active21 11 74 Mucosal colonic biopsies from Affymetrix Human Gene 20,358 Model
active UC patients and 1.0 ST Array evaluation
from controls
GSE75214-inactive21 11 23 Mucosal colonic biopsies from Affymetrix Human Gene 20,358 Model
inactive UC patients 1.0 ST Array evaluation
from controls
Table 1. Summary of datasets used in this study.
For each dataset, GEO2R23 was used to retrieve the mapping between probe IDs and gene symbols. Probe IDs without a
gene mapping were removed from further processing. Expression values for the mapped probe IDs were obtained using the
Python package GEOparse24. The expression values obtained were as provided by the corresponding authors.
Data Pre-processing
We performed the following steps for data pre-processing: (i) Calculating expression values per gene by taking the average
of expression values of all probes mapped to the same gene. (i) Handling missing values with K-Nearest Neighbours (KNN)
imputation method (KNNImputer) from the “missingpy” library in Python25. KNNImputer uses KNN to fill in missing values
by utilizing the values from nearest neighbours. We set the number of neighbours to 2 (n-neighbours=2) and we used uniform
weight.
To get our final training datasets we merged datasets GSE1152, GSE11223, and GSE22619 by taking the genes present in
all of them. The merged dataset has 39 UC samples and 38 controls, and 16,313 genes. These same genes were selected from
GSE75214 for validation. As the range of expression values across all datasets were different, we normalized the expression
values of the final merged dataset and validation dataset by calculating Z-scores per sample.
Model Generation
To create a model to discriminate between UC patients from healthy subjects, we selected the features (genes) using the
dimension reduction through perturbation theory (DRPT) feature selection method26. Let D= [A | b] be a dataset where b is
the class label and A is an m×n matrix with n columns (genes) and m rows (samples). There is only a limited number of genes
that are associated with the disease, and as such, a majority of genes are considered irrelevant. DRPT considers the solution x
of the linear system Ax= b with the smallest 2-norm. Hence, b is a sum of xiFi where Fi is the i-th column of A. Then each
component xi of x is viewed as an assigned weight to the feature Fi. So the bigger the |xi| the more important Fi is in connection
with b. DRPT then filters out features whose weights are very small compared to the average of local maximums over |xi|’s.
After removing irrelevant features, DRPT uses perturbation theory to detect correlations between genes of the reduced dataset.
Finally, the remaining genes are sorted based on their entropy.
2/10
Selected features were assessed using 5-fold cross-validation and support vector machines (SVMs) as the classifier. First,
we performed DRPT 100 times on the training dataset to generate 100 subsets of features. Then, to find the best subsets, we
performed 3 repetitions of stratified 5-fold cross-validation (CV) on the training dataset. We utilized average precision (AP) as
calculated by the function average_precision_score from the Python library scikit-learn27 (version 0.22.1) as the evaluation
metric to determine the best subset of genes among those 100 generated subsets. The four subsets with the highest mean AP
over the cross-validation folds were chosen for creating the candidate models. For each of four selected subset of features,
we created a candidate SVM model using all samples in the training dataset. To generate the models, we used the SVM
implementation available in the function SVC with parameter kernel=’linear’ from the Python library scikit-learn. To evaluate
the prediction performance of each of the ten models, we validated it on the GSE75214-active and GSE75214-inactive datasets.
In this step, we utilized the precision-recall curve (PRC) to assess the performance of the candidate models on unseen data. An
additional candidate model was created using the most frequently selected genes.
BioDiscML
BioDiscML28 is a biomarker discovery software that uses machine learning methods to analyze biological datasets. To compare
the prediction performance of our models with BioDiscML, we ran the software on our training dataset. 2/3 of the samples
(N=52) were utilized for training and the remaining 1/3 (N=25) for testing. Since the software generates thousands of models,
and we required only one model, we specified the number of best models as 1 in the config file (numberOfBestModels=1).
One best model out of all models was created based on the 10-fold cross-validated Area Under Precision-Recall Curve
(numberOfBestModelsSortingMetric= TRAIN-10CV-AUPRC) on the train set. We used Weka 3.829–31 to evaluate the
performance of the model generated by BioDiscML, on the GSE75214-active and GSE75214-inactive datasets. Selected
features by BioDiscML are C3orf36, ADAM30, SLS6A3, FEZF2, and GCNT3. In order to be able to use the model in Weka,
we loaded the training dataset as it was created by BioDiscML, which was one of the outputs of the software. This dataset has
six features, including selected genes and class labels, and 52 samples. We also modified our validation datasets by extracting
BioDiscML selected features. After loading the training and test dataset in Weka explorer, we loaded the model, and we entered
the classifier configuration as “weka.classifiers.misc.InputMappedClassifier -I -trim -W weka.classifiers.trees.RandomTree – -K
3 -M 1.0 -V 0.001 -S 1” which is the classifier’s set up in the generated model by BioDiscML.
Results
Feature selection reduced significantly the number of genes required to construct a classification model
We performed DRPT 100 times on the training dataset to select 100 subsets of features. Then we performed 5-fold cross-
validation to find the subsets with the highest mean average precision (AP) over the folds. The range of AP for the 100 subsets
is between 0.82 and 0.97, with an average of 0.91±0.03. Table 2 shows the ten subsets with the highest cross-validated AP
and the number of selected features (genes) on each subset. On average, DRPT selected 37.55±8.84 genes per subset.
Subset AP # of Features
Subset 10 0.97 42
Subset 51 0.97 47
Subset 58 0.97 32
Subset 83 0 .97 39
Subset 5 0.96 37
Subset 16 0.96 30
Subset 33 0.96 27
Subset 55 0.96 22
Subset 62 0.96 46
Subset 74 0.96 50
Table 2. Ten top subsets of genes with the highest cross-validated average AP.
Top five models are able to perfectly discriminate between active UC patients and controls
We selected the four top subsets with the highest mean AP, which are subsets 10, 51, 58, and 83 (Table 2), and created candidate
models based on them. Each candidate model was created using all samples on the training dataset and the features of the
corresponding subset. To identify the genes most relevant to discriminate between healthy and UC subjects, we looked at the
number of times each gene was selected by DRPT. On 100 DRPT runs, 211 genes were selected at least once. The upper plot
on Fig. 1 shows the number of times each gene was selected, and the lower plot shows the normal quantile-quantile (QQ) plot.
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Figure 1. Identifying the most frequently selected genes. Top: Number of times each gene was selected. Genes were sorted
based on the number of times they were selected by DRPT. Bottom: Normal QQ-plot. Horizontal line at 31 indicates the
threshold selected to deem a gene as frequently chosen.
Based on this plot, we saw that the observed distribution of the number of times a gene was selected deviates the most from a
Gaussian distribution above 31 times. We considered the genes selected by DRPT more than 31 times as highly relevant and
created a fifth model using 32 genes selected by DRPT at least 32 times over 100 runs.
In order to evaluate the prediction performance of the candidate models, each model was tested on the validation datasets,
and PRC was plotted for model assessment (Figs. 2, and 3). As the AP approximates the AUPRC32, we used AP to summarize
and compare the performance of these five models. All five candidate models achieved high predictive performance on the
validation dataset GSE75214-active with an average AP of 0.97± 0.03, while the average AP of these five models on the
validation dataset GSE75214-inactive was 0.60±0.06. The models with the best performance were the model created with
the 32 most frequently selected genes and subset 83 with an AP of 1 and 0.68 on GSE75214-active and GSE75214-inactive,
respectively. However, based on a Friedman test33 (p− value= 0.17), all five models have comparable performance on the
validation datasets. We chose the model generated with the 32 most frequently selected genes as our final model.
Our top models outperformed the model generated by BioDiscML.
The average AUPRC achieved by the model created by BioDiscML on both GSE75214-active and GSE75214-inactive datasets
was 0.798 and 0.544, respectively. Comparing the performance of our candidate models and the model created by BioDiscML
on the two validation datasets, we observed that we achieved better AUPRC on both datasets (AUPRC = 1 on the active dataset,
AUPRC = 0.68 on the inactive dataset). In terms of running time, subset selection by DRPT and final model creation and
validation, took 3 minutes, while the running time of BioDiscML to create all the models and output the best final model was
1,890 minutes.
Links between the most frequently selected genes and UC.
We used Ensembl REST API (Version 11.0)34 to find the associated phenotypes with each gene belonging to the subset of
the 32 most frequently selected genes (Table 3). Among these 32 genes, FAM118A is the only one with a known phenotypic
association with IBD and its subtypes. The evidence supporting the association of some of the other 31 genes with UC based
on phenotype is more indirect. For example, long term IBD patients are more susceptible to develop colorectal cancer35, and
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Figure 2. Precision-Recall Curve of Top Selected Subsets on GSE75214-active.
one of the 32 genes, TFRC, is associated with colorectal cancer. IBD patients are more prone to develop cardio vascular disease
which is associated with blood pressure and cholesterol36, and four of the most frequently selected genes (LIPF, MMP2, DMTN
and PPP1CB) are associated with blood pressure and cholesterol.
We looked at whether some of the 32 most frequently selected genes contained any of the 241 known IBD-associated
SNPs5. To do this, we utilized Ensembl’s BioMart37 website (Ensembl Release version 98 - September 2019) to retrieve the
genomic location of the 32 genes. We then used the intersectBed utility in BEDtools38 to find any overlap between the 241 IDB
risk loci and the genomic location of the 32 genes. None of the IBD-associated SNPs was located on our 32 genes. Similarly,
gene set enrichment analysis found no enriched GO term or pathway among these 32 genes. Additionally, these 32 genes are
not listed as top differentially expressed genes in previous studies on UC39, 40.
We searched the literature for links between the 32 genes and UC, and we found the following. MMP2 expression has been
found significantly increased in colorectal neoplasia in a mouse model of UC41 and MMP2 levels are elevated in IBD42. TFRC
has been found to have an anti-inflammatory effect on a murine colitis model43. KRT8 genetic variants have been observed in
IBD patients and it was suggested that these variants are a risk factor for IBD44. DUOXA2 has been shown to be critical in the
production of hydrogen peroxide within the colon and to be upregulated in active UC45.
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Figure 3. Precision-Recall Curve of Top Selected Subsets on GSE75214-inactive.
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Discussion
In a previous study where machine learning was employed to perform a risk assessment for Crohn’s disease and UC using
GWAS data46, a two-step feature selection strategy was used on a dataset containing 17,000 Crohn’s disease cases, 13,000
UC cases, and 22,000 controls with 178,822 SNPs. In that study, Wei et al reduced the number of features by filtering out
SNPs with p-values greater than 10−4 and then applied a penalized feature selection with L1 penalty to select a subset of SNPs.
We decided against filtering out genes based on an arbitrary p-value of statistical significance of differential expression, as
researchers are strongly advised against the use of p-values and statistical significance in relation to the null-hypothesis47, 48. To
avoid systematic experimental bias on the training data, we used three transcriptomic datasets from three separated studies, and
used an independent dataset to validate our top performing models.
Our 32-gene model achieved AP of 1 and 0.62 discriminating active UC patients from healthy donors, and inactive UC
patients from healthy donors, respectively. We found direct or indirect links to UC for about a quarter of the 32 most frequently
chosen genes. The remaining genes should be further investigated to find associations with UC. To put the performance of our
32-gene model into perspective, we looked at previous studies applying machine learning to create models for the diagnostic
of UC. Maeda et al49 extracted 312 features from endocystoscopy images to train a SVM to classify UC patients as active
or healing. This approach achieve 90% precision at 74% recall; which is lower than the one achieved by our 32-gene model
(Figs. 2, and 3). Yuan et al17 applied incremental feature selection and a SMO classifier (a type of SVM) on gene expression
data from blood samples to discriminate between healthy subjects, UC patients, and Crohn’s disease patients. The 10-fold
cross-validation accuracy of their best model using the expression values of 1170 genes to classify UC patients was 92.31%,
while our method obtained better accuracy than this with substantially less number of genes. In terms of potential for clinical
translation of a machine learning-based model, a model requiring to quantify the gene expression levels of fewer genes is more
suitable for the development of a new diagnostic test than one requiring the quantification of the expression levels of thousands
of genes. Using an efficient feature selection method such as DRPT and a SVM-classifier on gene expression data, we generated
a model that could facilitate the diagnosis of UC from expression measurements of 32 genes from colonic samples.
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